NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - General · USD

Eli Lilly and Company (LLY) Stock Analysis

Eli Lilly and Company (LLY) is a Drug Manufacturers - General stock listed on NYSE and quoted in US Dollar.

LLY

$1,149.36

−$10.24 (−0.88%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LLY with… →

LLY Key Statistics

As of Sep 4, 2026
Trading
Open
$1,150.61
Previous Close
$1,159.60
Day's Range
1,138.31–1,158.44
52-Week Range
712.05–1,292.65
Volume
2.22M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.50
Valuation
Market Cap
$1.02T
P/E Ratio
38.57
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
24.32
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.12
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.87
EPS (ttm)Profit attributable to each share over the last twelve months.
29.80
Financials (FY)
Revenue (FY)
$65.18B+44.70%
Net Income (FY)
$20.64B+94.90%
Profit marginThe share of revenue left as profit after all costs and taxes.
33.53%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
891.74M
1-Year Return
+55.69%
Dividend and dates
Dividend
$6.92+0.60%
Ex-Dividend Date
August 14, 2026
Earnings Date
October 29, 2026
Avg Volume
2.84M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LLY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+7.47%
2025+40.25%
2024+33.30%
2023+60.91%
2022+34.26%
2021+66.08%
2020+31.04%
2019+16.14%
2018+40.45%
2017+17.83%
2016 (partial year)−8.83%

As of September 4, 2026.

LLY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$65.18B$20.64B31.7%
2024$45.04B$10.59B23.5%
2023$34.12B$5.24B15.4%
2022$28.54B$6.24B21.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$65.18B$54.13B$29.70B$20.64B31.7%
2024$45.04B$36.63B$17.04B$10.59B23.5%
2023$34.12B$27.04B$10.33B$5.24B15.4%
2022$28.54B$21.91B$8.28B$6.24B21.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LLY Dividend History

$6.00+15.4% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$5.193—
2025$6.004+15.4%
2024$5.204+15.0%
2023$4.524+15.3%
YearDividends per sharePaymentsChange
2026 (partial year)$5.193—
2025$6.004+15.4%
2024$5.204+15.0%
2023$4.524+15.3%
2022$3.924+15.3%
2021$3.404+14.9%
2020$2.964+14.7%
2019$2.584+14.6%
2018$2.254+8.3%
2017$2.084+307.8%
2016$0.511—

Most recent payment: $1.73 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

LLY Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricLLYDrug Manufacturers - General medianvs median
P/E38.5724.6956% above
P/S ratio12.873.134.1x the median
Profit margin33.53%8.09%25.4 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Eli Lilly and Company (LLY) carries a market capitalisation of $1.02T. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. The company reports 50,000 employees.

LLY last closed at $1,149.36 on September 4, 2026. That is −$10.24 (−0.88%) against the previous close. The 52-week range on file runs from $712.05 to $1,292.65. The latest close sits 61.42% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $65.18B. Against the prior fiscal year total of $45.04B, that is a change of +44.70%. Net income for the same year was $20.64B. That is +94.90% against the prior fiscal year. The reported profit margin is 33.53%. That is 25.4 percentage points above the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to 29.8.

Across the 4 fiscal years on file, revenue moves from $28.54B in 2022 to $65.18B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 38.57 times earnings. That is 56.22% above the Drug Manufacturers - General median of 24.69. The forward P/E on file is 24.32. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.12. The price-to-sales ratio is 12.87. On price-to-sales that is 4.1 times the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Over the trailing twelve months the price has returned +55.69%. Across 10 years the annualized return works out at +33.13%. The reported beta is 0.5. Annualized volatility over the trailing 10 years is 30.54%.

Growth & Income

Shareholders receive a dividend, yielding 0.6% on the latest price. That is 2.1 percentage points below the Drug Manufacturers - General median yield of 2.7%. The indicated annual rate is $6.92 a share. The ex-dividend date on file is August 14, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $5.19 a share. The year before, 2025, totalled $6.00 a share.

So far in 2026 the price is +7.47%. The strongest complete calendar year on file is 2021 at +66.08%; the weakest is 2019 at +16.14%. Of the 9 complete calendar years on file, 9 finished higher.

Peer Comparison

Eli Lilly and Company (LLY) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5
Merck & Co., Inc. MRK $370.89B 122.2

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Eli Lilly and Company trades at a P/E of 38.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B

 AMGN

Amgen Inc.

$236.38B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B

 GILD

Gilead Sciences, Inc.

$187.23B
View all Healthcare stocks →

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Visit website →